Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
July 18 2024 - 3:13PM
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for
minimally invasive endovascular intervention, today announced the
appointment of Nachum “Homi” Shamir to its Board of Directors.
Mr. Shamir most recently served as Chairman and
Chief Executive Officer of Luminex Corporation from 2014 through
its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to
Luminex, Mr. Shamir served as President and Chief Executive Officer
of Given Imaging from 2006 through its sale to Covidien for $1
Billion in 2014. He currently serves as Chairman of Mediwound, a
publicly-traded leader in enzymatic therapeutics for burn and
wound-care, and SSI Diagnostica, a private-equity owned diagnostics
company. Mr. Shamir brings to Stereotaxis significant experience
and expertise in growing global commercial organizations, scaling
high-technology medical device operations, and successfully
executing mergers and acquisitions.
“I am impressed by Stereotaxis’ comprehensive
strategy and excited to join the company as it nears significant
inflection points,” said Mr. Shamir. “I look forward to
contributing to the efforts to grow substantial global commercial
and operational capabilities, and to the continued refinement of a
strategy that will ensure robotics transforms endovascular
surgery.”
“We are delighted to have Homi join the
Stereotaxis Board of Directors,” said David Fischel, Chairman and
CEO. “Stereotaxis is blessed with a Board that brings
highly-relevant skillsets and complementary expertise as we advance
an ambitious strategy. We look forward to benefiting from Homi’s
contributions.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts: David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Nov 2023 to Nov 2024